logo
Plus   Neg
Share
Email

AstraZeneca: Lynparza Recommended For Marketing Authorisation In EU

AstraZeneca Plc (AZN.L,AZN) and Merck & Co., Inc.(MRK) announced Monday that the European Medicines Agency or EMA recommended Lynparza (olaparib) for marketing authorisation in the European Union. The recommendation is for the 1st-line maintenance treatment of patients with germline BRCA-mutated or gBRCAm metastatic pancreatic cancer.

EMA's Committee for Medicinal Products for Human Use or CHMP based its positive opinion on results from the Phase III POLO trial, which were published in The New England Journal of Medicine.

The trial demonstrated that Lynparza nearly doubled the time patients with gBRCAm metastatic pancreatic cancer lived without disease progression or death to a median of 7.4 months versus 3.8 months on placebo.

In the trial, the drug's safety and tolerability profile was consistent with previous trials.

The CHMP recommendation is for maintenance treatment with Lynparza for adult patients with germline BRCA1/2 mutations who have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of platinum treatment within a 1st-line chemotherapy regimen.

Lynparza is approved in the US and several other countries as a 1st-line maintenance treatment for patients with gBRCAm metastatic pancreatic cancer based on the Phase III POLO trial, with ongoing regulatory reviews in the EU and other jurisdictions.

In the U.S., the drug was recently approved for patients with homologous recombination repair or HRR gene-mutated metastatic castration-resistant prostate cancer.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Polaris Industries Inc. is recalling certain Ranger and General Utility, as well as All-Terrain vehicles citing risks of crash, the U.S. Consumer Product Safety Commission said in a statement. The Medina, Minnesota-based company has called back about 26,730 units of Model Year 2019 - 2020 Ranger XP 1000 & Model Year 2020 General XP 1000 Utility vehicles. Gilead Sciences Inc. (GILD) said Friday that the European Commission has granted conditional marketing authorization for Veklury or remdesivir as a treatment for SARS-CoV-2 infection, the virus that causes COVID-19. FedEx is asking NFL team Washington Redskins to change its name for its racist connotations. The delivery services company, which is a major sponsor for the team, made the suggestion following increasing pressure from its investors amid the ongoing protests against racial injustice and inequality that arose from the killing of African-American George Floyd.
Follow RTT